Tahira Younis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tahira Younis has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Ali Raza Ishaq
State Key Laboratory of Biocatalysis and Enzyme Engineering, Environmental Microbial Technology Center of Hubei Province, College of Life Science, Hubei University, Wuhan, China
2 shared publicationsAbdulaziz Alamri
Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia
1 shared publicationAneela Bashir
Key Laboratory of Biorheological Science and Technology of Ministry of Education, Bioengineering College, Chongqing University, Chongqing, China
1 shared publicationAsfandyar
State Key Laboratory of Biocatalysis and Enzyme Engineering, Environmental Microbial Technology Center of Hubei Province, College of Life Science, Hubei University, Wuhan, China
1 shared publicationAyman M. Al-Qaaneh
Faculty of Allied Medical Sciences, Al-Balqa Applied University (BAU), Al-Salt, Jordan
1 shared publication- Bilal Rasool
Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad, Punjab, Pakistan
1 shared publication
Latest Publications
- Open Access
- 18 September 2026
- Published by Springer Nature in Scientific Reports
Integrated experimental and computational evaluation of the wound-healing potential of Fraxinus xanthoxyloides bark extract
Wound healing remains a significant clinical challenge, driving the need for innovative natural therapeutics. This study investigated F. xanthoxyloides bark methanolic extract (FXBM) using integrated in vitro, in vivo, and in silico approaches. LC-ESI-MS/MS identified eight bioactive compounds: gallic acid, cinnamaldehyde, coumaric acid, sinapic acid, vanillic acid, caffeic acid, hydroxybenzoic acid, and quercetin. FXBM demonstrated high cell viability (122.35 ± 2.72% and 126.02 ± 0.9%) at 20 µg/mL in HaCaT keratinocytes and NIH3T3 fibroblasts, respectively. Scratch assays showed dose-dependent wound closure, with 20 µg/mL FXBM achieving near-complete closure in both cell lines after 48 h. It also protected HaCaT cells from apoptosis, reducing total apoptotic cells by 75% at 20 µg/mL. In BALB/c mice, 10% FXBM gel achieved 99.79 ± 0.083% wound closure by day 21, comparable to 1% silver sulfadiazine. Histology confirmed enhanced collagen deposition, re-epithelialization, and hair follicle regeneration. FXBM activated antioxidant defenses by reducing malondialdehyde and enhancing superoxide dismutase and catalase activities. It dually regulated inflammation by decreasing TNF-α, IL-6, and IL-1β while upregulating VEGF, and activated the Nrf2/HO-1 pathway and MMP-1-mediated tissue remodeling. In silico analysis confirmed Lipinski compliance; network pharmacology identified EGFR, STAT3, MMP9, TLR4, and RELA as key targets, with GO/KEGG implicating oxidative stress, NF-κB, and MAPK signaling. Molecular docking showed strong binding affinities, with sinapic acid exhibiting highest affinity for MMP-1 (− 6.8 kcal/mol). These findings establish F. xanthoxyloides as a promising wound-healing candidate for clinical translation.
- 18 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessIntegrated experimental and computational evaluation of the wound-healing potential of Fraxinus xanthoxyloides bark extract
Wound healing remains a significant clinical challenge, driving the need for innovative natural therapeutics. This study investigated F. xanthoxyloides bark methanolic extract (FXBM) using integrated in vitro, in vivo, and in silico approaches. LC-ESI-MS/MS identified eight bioactive compounds: gallic acid, cinnamaldehyde, coumaric acid, sinapic acid, vanillic acid, caffeic acid, hydroxybenzoic acid, and quercetin. FXBM demonstrated high cell viability (122.35 ± 2.72% and 126.02 ± 0.9%) at 20 µg/mL in HaCaT keratinocytes and NIH3T3 fibroblasts, respectively. Scratch assays showed dose-dependent wound closure, with 20 µg/mL FXBM achieving near-complete closure in both cell lines after 48 h. It also protected HaCaT cells from apoptosis, reducing total apoptotic cells by 75% at 20 µg/mL. In BALB/c mice, 10% FXBM gel achieved 99.79 ± 0.083% wound closure by day 21, comparable to 1% silver sulfadiazine. Histology confirmed enhanced collagen deposition, re-epithelialization, and hair follicle regeneration. FXBM activated antioxidant defenses by reducing malondialdehyde and enhancing superoxide dismutase and catalase activities. It dually regulated inflammation by decreasing TNF-α, IL-6, and IL-1β while upregulating VEGF, and activated the Nrf2/HO-1 pathway and MMP-1-mediated tissue remodeling. In silico analysis confirmed Lipinski compliance; network pharmacology identified EGFR, STAT3, MMP9, TLR4, and RELA as key targets, with GO/KEGG implicating oxidative stress, NF-κB, and MAPK signaling. Molecular docking showed strong binding affinities, with sinapic acid exhibiting highest affinity for MMP-1 (− 6.8 kcal/mol). These findings establish F. xanthoxyloides as a promising wound-healing candidate for clinical translation.
- Open Access
- 4 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0346328
Protective effects of Fraxinus xanthoxyloides bark in alloxan-induced diabetic rats: A phytochemical and pharmacological approach
Fraxinus xanthoxyloides Wall. ex DC (Family-Oleaceae) is a tiny tree found in arid highlands, often referred to as “Afghan ash”. This study aimed to explore F. xanthoxyloides bark extract as a potential anti-diabetic agent by conducting GC-MS analysis along with in vitro and in vivo studies. F. xanthoxyloides bark methanol extract (FXBM) was fractionated with n-hexane (FXBH), followed by chloroform (FXBC), ethyl acetate (FXBE), and residual aqueous fraction (FXBA). GC-MS and HPLC-MS analysis of the total extract were performed. The inhibitory activities against α-amylase, α-glucosidase, and DPP4 were assessed for the extract and its fractions. The in vivo study included five groups: control group, diabetic control, groups pretreated with alloxan (150 mg/kg) + glibenclamide (5 mg/kg), group pretreated with alloxan (150 mg/kg) + FXBH (200 mg/kg), and group pretreated with alloxan (150 mg/kg) + FXBH (400 mg/kg). Further, a histopathological investigation was conducted. GC-MS analysis of FXBM revealed the presence of 17 compounds predominated by esters (17.9%), polyols (16.35%), and O -glycosides (12.24%). Among all extract/fractions, FXBH showed maximum α-amylase, α-glucosidase, and DPP4 inhibition when compared to acarbose and berberine, respectively. It also achieved the highest glucose uptake among all extract/fractions when compared with metformin. HPLC-DAD analysis showed the presence of gallic acid (3.29 µg/mg), catechin (4.23 µg/mg), caffeic acid (6.05 µg/mg), ferulic acid (2.99 µg/mg), and quercetin (6.4 µg/mg). FXBH-treated rats showed a significant increase in body weight and reduced blood glucose levels ( p < 0.05) from days 1–30. The biochemical parameters like triglyceride, low-density lipoprotein, cholesterol, lipase, amylase, C-reactive protein, alanine aminotransferase, aspartate aminotransferase, creatinine, HbA1c, and urea were decreased, while high-density lipoprotein was elevated, compared to diabetic control. Histopathological studies demonstrated restoration of pancreatic β-cells. In conclusion, F. xanthoxyloides bark extract exhibited potential antidiabetic effects; meanwhile, further studies are recommended to characterize the pharmacodynamics, pharmacokinetics, and synergistic effects with standard drugs.
- 4 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0346328
Open AccessProtective effects of Fraxinus xanthoxyloides bark in alloxan-induced diabetic rats: A phytochemical and pharmacological approach
Fraxinus xanthoxyloides Wall. ex DC (Family-Oleaceae) is a tiny tree found in arid highlands, often referred to as “Afghan ash”. This study aimed to explore F. xanthoxyloides bark extract as a potential anti-diabetic agent by conducting GC-MS analysis along with in vitro and in vivo studies. F. xanthoxyloides bark methanol extract (FXBM) was fractionated with n-hexane (FXBH), followed by chloroform (FXBC), ethyl acetate (FXBE), and residual aqueous fraction (FXBA). GC-MS and HPLC-MS analysis of the total extract were performed. The inhibitory activities against α-amylase, α-glucosidase, and DPP4 were assessed for the extract and its fractions. The in vivo study included five groups: control group, diabetic control, groups pretreated with alloxan (150 mg/kg) + glibenclamide (5 mg/kg), group pretreated with alloxan (150 mg/kg) + FXBH (200 mg/kg), and group pretreated with alloxan (150 mg/kg) + FXBH (400 mg/kg). Further, a histopathological investigation was conducted. GC-MS analysis of FXBM revealed the presence of 17 compounds predominated by esters (17.9%), polyols (16.35%), and O -glycosides (12.24%). Among all extract/fractions, FXBH showed maximum α-amylase, α-glucosidase, and DPP4 inhibition when compared to acarbose and berberine, respectively. It also achieved the highest glucose uptake among all extract/fractions when compared with metformin. HPLC-DAD analysis showed the presence of gallic acid (3.29 µg/mg), catechin (4.23 µg/mg), caffeic acid (6.05 µg/mg), ferulic acid (2.99 µg/mg), and quercetin (6.4 µg/mg). FXBH-treated rats showed a significant increase in body weight and reduced blood glucose levels ( p < 0.05) from days 1–30. The biochemical parameters like triglyceride, low-density lipoprotein, cholesterol, lipase, amylase, C-reactive protein, alanine aminotransferase, aspartate aminotransferase, creatinine, HbA1c, and urea were decreased, while high-density lipoprotein was elevated, compared to diabetic control. Histopathological studies demonstrated restoration of pancreatic β-cells. In conclusion, F. xanthoxyloides bark extract exhibited potential antidiabetic effects; meanwhile, further studies are recommended to characterize the pharmacodynamics, pharmacokinetics, and synergistic effects with standard drugs.
- Open Access
- 2 May 2023
- Published by Springer Nature in Microbial Cell Factories
- Vol. 22 (1) , 1-23
Molecular mechanism of engineered Zymomonas mobilis to furfural and acetic acid stress
Acetic acid and furfural (AF) are two major inhibitors of microorganisms during lignocellulosic ethanol production. In our previous study, we successfully engineered Zymomonas mobilis 532 (ZM532) strain by genome shuffling, but the molecular mechanisms of tolerance to inhibitors were still unknown. Therefore, this study investigated the responses of ZM532 and its wild-type Z. mobilis (ZM4) to AF using multi-omics approaches (transcriptomics, genomics, and label free quantitative proteomics). Based on RNA-Seq data, two differentially expressed genes, ZMO_RS02740 (up-regulated) and ZMO_RS06525 (down-regulated) were knocked out and over-expressed through CRISPR-Cas technology to investigate their roles in AF tolerance. Overall, we identified 1865 and 14 novel DEGs in ZM532 and wild-type ZM4. In contrast, 1532 proteins were identified in ZM532 and wild-type ZM4. Among these, we found 96 important genes in ZM532 involving acid resistance mechanisms and survival rates against stressors. Furthermore, our knockout results demonstrated that growth activity and glucose consumption of mutant strains ZM532∆ZMO_RS02740 and ZM4∆ZMO_RS02740 decreased with increased fermentation time from 42 to 55 h and ethanol production up to 58% in ZM532 than that in ZM532∆ZMO_RS02740. Hence, these findings suggest ZMO_RS02740 as a protective strategy for ZM ethanol production under stressful conditions.
- 2 May 2023
- Published by Springer Nature in Microbial Cell Factories
- Vol. 22 (1) , 1-23
Open AccessMolecular mechanism of engineered Zymomonas mobilis to furfural and acetic acid stress
Acetic acid and furfural (AF) are two major inhibitors of microorganisms during lignocellulosic ethanol production. In our previous study, we successfully engineered Zymomonas mobilis 532 (ZM532) strain by genome shuffling, but the molecular mechanisms of tolerance to inhibitors were still unknown. Therefore, this study investigated the responses of ZM532 and its wild-type Z. mobilis (ZM4) to AF using multi-omics approaches (transcriptomics, genomics, and label free quantitative proteomics). Based on RNA-Seq data, two differentially expressed genes, ZMO_RS02740 (up-regulated) and ZMO_RS06525 (down-regulated) were knocked out and over-expressed through CRISPR-Cas technology to investigate their roles in AF tolerance. Overall, we identified 1865 and 14 novel DEGs in ZM532 and wild-type ZM4. In contrast, 1532 proteins were identified in ZM532 and wild-type ZM4. Among these, we found 96 important genes in ZM532 involving acid resistance mechanisms and survival rates against stressors. Furthermore, our knockout results demonstrated that growth activity and glucose consumption of mutant strains ZM532∆ZMO_RS02740 and ZM4∆ZMO_RS02740 decreased with increased fermentation time from 42 to 55 h and ethanol production up to 58% in ZM532 than that in ZM532∆ZMO_RS02740. Hence, these findings suggest ZMO_RS02740 as a protective strategy for ZM ethanol production under stressful conditions.
- Open Access
- 1 December 2022
- Published by Elsevier in Saudi Journal of Biological Sciences
- Vol. 30 (2) , 103518
Exploration of polyacrylamide microplastics and evaluation of their toxicity on multiple parameters of Oreochromis niloticus
- 1 December 2022
- Published by Elsevier in Saudi Journal of Biological Sciences
- Vol. 30 (2) , 103518
Open AccessExploration of polyacrylamide microplastics and evaluation of their toxicity on multiple parameters of Oreochromis niloticus